24 key monitoring of large varieties of winning bid results published (attached list)

On August 20th, The Pharmaceutical Network issued a notice on the audit of the information on the key monitoring of reasonable drug bargaining declarations and the results of the finalists issued by Wuhan Pharmaceutical Centralized Belt Purchase Service Platform.
according to the notice, Wuhan City in 2020 focus on monitoring reasonable drug bargaining quotation work has been completed, is now the enterprise and product declaration information audit and the results of the proposed shortlist publicity, publicity period from August 18 to August 24.
Of these, 24 drugs are to be shortlisted, involving Yangzijiang, Qilu, Koren, Renfu and many other well-known pharmaceutical enterprises, the proposed shortlist is as follows: as early as August 3, Wuhan City Pharmaceutical Centralized Belt Purchase Service Platform issued the "Wuhan City 2020 key monitoring reasonable drug bargaining regulations" and "focus on monitoring reasonable drug bargaining drug catalog."
this is the first time a drug has been priced in a key monitoring.
it is learned that the bargaining procurement catalog has a total of 30 generic names, the maximum price of key monitoring drugs for the enterprise provincial network minimum price of 0.7 times, that is, a minimum price reduction of 30%.
24 products involved in the above-mentioned finalists, involving 19 generic names, i.e. 11 generic names were undefined.
focus on monitoring drugs, it is becoming more and more difficult for Wuhan's first water test to focus on monitoring drug bargaining procurement, the main purpose is still to control fees, reduce the cost of drugs for patients.
well known, the current list of drugs listed in the focus of monitoring, the market size is very large.
according to the Minet database, the state's focus on monitoring drug catalogs of 20 varieties, in 2018 in China's public hospital sales totaled 65.28 billion yuan, of which 5 varieties market size of more than 5 billion yuan.
by including these drugs in a focused surveillance catalog and limiting clinical use, we can control the growth of sales of these drugs, and we can reduce the market size of these drugs by bargaining for lower prices.
addition, the focus on monitoring the directory of the "good partner" - health care control fees, is a strong help in the "war" on fee control.
As early as March 2017, Fujian Province issued the "health insurance payment standard", the clinical value of drugs has become an important standard, a large number of complementary drugs, nutritional drugs reimbursement ratio was "waist chopping", only 50% reimbursement, non-base medicine injections will not be reimbursed.
this operation, the hospital drug treatment structure has changed significantly.
currently in Fujian Province Pharmaceutical Mining Center monthly release of drug sales data, including Chinese medicine injections, complementary drugs, nutritional drugs and other categories, has been completely disappeared in the monthly sales of the top 20 list.
In recent years, with the introduction of relevant national policies, all over the key monitoring of drugs strict control, from the key monitoring of drug market trends in recent years, the vast majority of varieties from 2015 onwards, the annual market growth rate and even sales are declining.
, for example, the market has been on a downward trend year-on-year since 2017, with negative growth becoming more and more evident from 2018.
(data source: Minet) In addition, from the point of view of focused monitoring, controlling the overall dosing of drugs has a lot to do with doctors' prescriptions.
to control the use of large quantities of drugs at the source, in order to promote clinical rational use of drugs.
As early as 2015, the General Office of the State Council issued "guidance on improving the centralized procurement of drugs in public hospitals" and the former State Health planning commission issued "on the implementation of the improvement of public hospitals drug centralized procurement guidance notice", it is clear to strictly control the large prescriptions of hospitals, will "focus on tracking and monitoring auxiliary drugs, hospitals used drugs, and effectively reduce unreasonable drug use" as an important measure to regulate the use of drugs in hospitals.
years, the whole country has carried out medical institutions inspection and supervision and inspection, many of which found that there is a problem of large prescriptions.
strictly investigate unreasonable drug use, prohibit doctors from prescribing large, for some of the existence of promotional activities of the enterprise sales will also be affected.
, especially the reform of health insurance payment gradually advanced and perfected, for some enterprises that do not consider rational drug use, only consider the amount, is a major blow.
therefore, with the tightening of national control, not only focus on monitoring varieties, those markets are particularly hot, clinical sales of particularly large drugs, will also face an inescapable test of strict control.
.